Episode 489: LIVE from ILADS: Jackie Meinhardt - Exploring Cutting-Edge Approaches in Lyme Disease Treatment

In this live episode from the International Lyme and Associated Diseases Society (ILADS) Conference, Jackie Meinhardt, a functional medicine nurse practitioner and neuroscience researcher at the Amen Clinic, shares her expertise on treating Lyme disease and associated conditions. Jackie discusses her approach to functional and integrative medicine, the challenges faced by patients with chronic Lyme, and the latest research on difficult-to-treat cases. Key Takeaways: Jackie Meinhardt’s Background & Expertise: Jackie Meinhardt holds a Doctor of Nursing Practice (DNP) from Georgetown University and has extensive training in functional medicine. She collaborates with Dr. Daniel Amen at the Amen Clinic in Washington, D.C., where she works on brain health and cognitive function. Involvement with ILADS: Jackie has been an active participant in the ILADS community, emphasizing the importance of educating both healthcare providers and patients about the latest developments in Lyme disease treatments. Research on Difficult-to-Treat Lyme Disease Patients: Through her research, Jackie has observed critical patterns in hard-to-treat Lyme patients, focusing on plasminogen activation inhibitors and biofilm. These findings have significantly influenced her clinical strategies and contributed to improved patient outcomes. Challenges in Lyme Disease Care: Jackie discusses the barriers Lyme disease patients face in accessing quality care and highlights the need for changes in public policy and medical practices to improve treatment options. The Role of ILADS in Advancing Lyme Disease Care: Jackie underscores the importance of platforms like ILADS for sharing research findings and influencing the standard of care in Lyme disease treatment. Resources & Links: Follow the latest ILADS updates at ILADS.org Learn more about Jackie Meinhardt at Amen Clinics - Jackie Meinhardt Stay connected with Tick Boot Camp: Website | Instagram | Facebook | YouTube | TikTok | Twitter (X)